Network Insights Methodology Get Access

Merck

ORG Health Care / Pharmaceuticals Momentum 15.2 NORMAL Primary: Spectral Shift

$59B revenue (2025), Rahway-based pharma giant cutting Zepatier pricing steeply as hepatitis C market competition intensifies. Divested Organon spinoff to Sun Pharma for $11.75B; now focused on oncology, immunology, and infectious disease.

Merck spun off Organon (women's health and established pharmaceuticals) in 2021; Sun Pharma acquired Organon for $11.75B in 2024. Merck entered antibody discovery agreement with Infinimmune. Recent pricing action on Zepatier (sofosbuvir/velpatasvir, Hep C treatment).
-0.14
PSI Score
15.2
Momentum
1%
Confidence
7
Connections
Connected Entities
Novartis Pfizer Sanofi China European Union Eli Lilly India Bay Area FDA EPA
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-06 2026-05-03 7 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.640
Narrative Drift
0.000
Spectral Shift
529.786
Sentiment-Momentum Divergence
0.000
Source Concentration
0.961
Peer Comparison
N/A
Sector Rank
+0.00
Peer Z-Score
0%
Sector Percentile
Network Analysis
7 Degree Centrality
Centrality History
2026-04-06 2026-05-03 7 0 Degree Mentions
EntityWeight StatusFirst Seen
Novartis 46 STRENGTHENED
Pfizer 46 STRENGTHENED
Sanofi 4 NEW
China 2 STABLE
European Union 2 STABLE
Eli Lilly 2 NEW
India 2 STABLE
Bay Area 2 NEW
FDA 2 STABLE
EPA 1 STABLE
Article Coverage (0)
DateLaneTitle

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-03 ← Intelligence Network